Fiscal Year 2011 Annual Review of Otic Antibiotics

Oklahoma HealthCare Authority April 2012

Prior Authorization of Otic Antibiotics

Otic Antibiotics						
Tier 1	Tier 2	Special PA*				
Ofloxacin (Floxin Otic®)	Ciprofloxacin, Dex or HC (Ciprodex®, Cipro HC®, Cetraxal® Drop.)	Acetic Acid, HC (Acetasol HC®, Vosol HC®)				
Acetic acid (Vosol®, Acetasol®)	Neomycin,Polymixin B, HC, thonzonium (Cortisporin TC®)	Acetic Acid, aluminum (Borofair®)				
Neomycin, Polymixin B, HC (Cortisporin®, Cortomycin®, Pediotic®)	Neomycin,Colistin, HC (Coly-Mycin®, and Coly Mycin-ES®)	Acetic Acid/antpy/bcain/polico/al acet 5.4%-1.4% drops (AABP®, PR Otic®, Otic Edge®)				
Chloroxylenol/Pramoxine (Pramotic®)	Chloroxylenol/Pramoxine/Zinc (Zinotic®, Zinotic ES®, Chlorpram Z®)	Antipyrine, benzocaine, glycerin, zinc 5.4-1-2-1% (Neotic®)				
Antipyrine	Chloroxylenol, benzocaine, and HC (Trioxin®)					

Prior Authorization Criteria

- 1. Member must have adequate 14-day trial of at least two Tier 1 medications, or
- 2. Approval may be granted if there is a unique FDA approved indication not covered by Tier 1 products or infection by organism not known to be covered by any of the Tier 1 agents.
- 3. A ciprofloxacin combination product may be approved after a recent 7 to 10 day trial of ofloxacin and dexamethasone 0.1% solution.

Criteria for Acetasol HC®, Vosol® HC, Borofair®, AABP®, PR Otic®, Otic Edge® and Neotic®:

- 1. Diagnosis of acute otitis externa.
- 2. Recent (within 6 months) trials with all other commonly used topical otic anti-infectives that have failed to resolve infection, or
- 3. Allergy to all available products and failure of acetic acid alone.


Utilization of Otic Antibiotics

Utilization Trends


Fiscal Year	Members*	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2010	27,870	35,730	\$1,488,145.69	\$41.65	\$4.21	312,465	353,085
2011	28,806	39,685	\$817,031.97	\$20.59	\$2.11	337,256	386,536
%Change	3.40%	11.10%	-45.10%	-50.60%	-49.90%	7.90%	9.50%
Change	936	3,955	-\$671,113.72	-\$21.06	-\$2.10	24,791	33,451

^{*} Total number of unduplicated members.

Demographics for FY 2011




Prescriber Specialty by Claims and Cost for FY 2011



Prior Authorization of Fibric Acid Derivatives

There were a total of 1,299 petitions submitted for this PBPA category during Fiscal Year 2011. Computer edits are in place to look for Tier 1 medications, and if detected, the medication will not require a petition. The following chart shows the status of the submitted petitions:



Market News and Update

Anticipated Patent Expirations:

- 1. Ciprodex® 2020
- 2. Cipro HC® 2015
- 3. Cetraxal® May 2012

Recommendation

The College of Pharmacy recommends continued monitoring of this category.

Utilization Details of Otic Antibiotics: FY 2011

Chemical Name	Brand Name	Claims	Members*	Cost	Cost/ Day	Claims/ Member	% Cost
Ofloxacin	OFLOXACIN DRO 0.3%OTIC	22,750	16,417	\$331,372.10	\$1.63	1.39	40.56%
Neomycin-Polymyxin-HC	NEO/POLY/HC SUS 1% OTIC	10,296	8,991	\$284,681.14	\$2.71	1.15	34.84%
Neomycin-Polymyxin-HC	NEO/POLY/HC SOL 1% OTIC	5,604	4,950	\$114,787.58	\$1.90	1.13	14.05%
Cipro-Dexamethasone	CIPRODEX SUS 0.3-0.1%	561	463	\$70,932.41	\$11.32	1.21	8.68%
Acetic Acid 2%	ACETIC ACID SOL 2% OTIC	308	240	\$10,227.56	\$1.09	1.28	1.25%
Pram-Chloroxylenol	PRAMOXINE/ DRO CHLORXYL	111	95	\$1,772.29	\$1.20	1.17	0.22%
Neomycin-Polymyxin-HC	CORTOMYCIN SUS 1% OTIC	15	14	\$418.45	\$3.01	1.07	0.05%
Neomycin-Polymyxin-HC	CORTOMYCIN SOL 1% OTIC	14	13	\$234.89	\$1.97	1.08	0.03%
Ciprofloxacin-HC	CIPRO HC SUS OTIC	14	14	\$1,695.57	\$11.94	1	0.21%
Neomycin-Colistin-HC-	CORTISPORIN SUS -TC OTIC	6	6	\$462.24	\$7.83	1	0.06%
Ciprofloxacin	CETRAXAL SOL 0.2%	2	2	\$182.04	\$10.71	1	0.02%
Acetic Acid 2% Alum Ac	ACE ACD/ALUM SOL 2% OTIC	2	2	\$134.76	\$7.93	1	0.02%
Chloroxyl-Glyc-Pram-Zn	ZINOTIC DRO	1	1	\$119.55	\$11.96	1	0.01%
HC w/ Acetic Acid	HC/ACET ACID SOL OTIC	1	1	\$11.39	\$1.63	1	0.00%
	Totals	39,685	28,806	\$817,031.97	\$2.11	1.38	100.00%

^{*}Unduplicated total number of members.